Publications by authors named "A Randrup Thomsen"
Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG. Here we report results from Arm C, restricted to patients with DIPG.
View Article and Find Full Text PDFUnlabelled: β-arrestins (βarrs) are key regulators of G protein-coupled receptors (GPCRs), essential for modulating signaling pathways and physiological processes. While current pharmacological strategies target GPCR orthosteric and allosteric sites, as well as G protein transducers, comparable tools for studying βarrs are lacking. Here, we present the discovery and characterization of novel small-molecule allosteric inhibitors of βarrs through comprehensive biophysical, biochemical, pharmacological, and structural analyses.
View Article and Find Full Text PDFArticle Synopsis
- This study examines how well different types of Granular Activated Carbon (GAC) and an anion exchange resin can remove PFAS and other contaminants from groundwater used for drinking water production.
- GAC was effective initially, showing low breakthrough rates for contaminants, but its efficiency decreased over time; however, the resin improved the removal of certain acid compounds but not all.
- Some contaminants were effectively removed, but the use of resin filters led to the detection of new contaminants in the treated water, raising concerns about drinking water safety.
Purpose: To investigate if the initial treatment response can predict the 1-year treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) treated according to the observe-and-plan (O&P) regimen.
Methods: In this prospective cohort study, treatment-naïve patients with nAMD were enrolled consecutively and followed for 1 year while being treated according to the O&P regimen. The treatment response was determined initially post-loading doses and after 1 year.
Nerve growth factor (NGF) monoclonal antibodies inhibit chronic pain yet failed to gain approval due to worsened joint damage in osteoarthritis patients. We report that neuropilin-1 (NRP1) is a co-receptor for NGF and tropomyosin-related kinase A (TrkA) pain signaling. NRP1 was coexpressed with TrkA in human and mouse nociceptors.
View Article and Find Full Text PDF